Quarterly ResultMay 12, 2026, 08:12 AM
NeuroOne Q2 Product Revenue Up 72% to $2.4M; Net Loss $2.1M
AI Summary
NeuroOne Medical Technologies reported fiscal Q2 2026 financial results, with product revenue increasing 72% year-over-year to $2.4 million. The company posted a net loss of $2.1 million, or ($0.25) per share. Operationally, NeuroOne successfully completed 16 Trigeminal Neuralgia cases with positive patient outcomes, regained Nasdaq compliance, and completed a stage 2 audit for ISO 13485 certification to support international expansion. The company also announced the appointment of a new Chief Business Officer and a significant investment from a high-net-worth individual.
Key Highlights
- Product revenue was $2.4 million, a 72% increase year-over-year.
- Net loss was $2.1 million, or ($0.25) per basic and diluted share.
- Cash and cash equivalents were $2.8 million as of March 31, 2026.
- Successfully completed 16 Trigeminal Neuralgia cases, with all patients reportedly pain free.
- New high-net-worth investor acquired approximately 7.4% of outstanding common stock.
- David Wambeke appointed Chief Business Officer and purchased 1,000,000 shares.
- Regained Nasdaq compliance with the minimum bid price requirement.
- Completed stage 2 audit for ISO 13485 certification, enabling international distribution.